Horizon : New Analysis Supports Efficacy Of UPLIZNA For Neuromyelitis Optica Spectrum Disorder

Horizon Therapeutics plc (HZNP) said a new post hoc analysis of the UPLIZNA N-MOmentum Phase 2/3 pivotal trial showed that prior rituximab exposure did not impact the efficacy of UPLIZNA, and that UPLIZNA demonstrated comparable efficacy to trial participants without prior exposure to rituximab.

The analysis has been published in Multiple Sclerosis and Related Disorders.

Of the 17 participants who had previously been treated with rituximab, 13 were randomly assigned to the UPLIZNA treatment group.

The analysis showed that all seven participants who had pre-study attacks despite rituximab use did not experience any attacks after being treated with UPLIZNA.

UPLIZNA is B-cell-depleting humanized monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment of NMOSD in adults who are anti-aquaporin-4 (AQP4) antibody positive. UPLIZNA is a next-generation B-cell-depleting therapy engineered for optimized efficacy and tolerability.

UPLIZNA specifically targets and depletes CD19-expressing B cells, including plasmablasts and some plasma cells not targeted by anti-CD20 therapies like rituximab. Rituximab is not approved by the FDA for the treatment of NMOSD.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT